Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aclaris Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Aclaris Therapeutics Inc’s stock price such as:

• Aclaris Therapeutics Inc’s current stock price and volume
• Why Aclaris Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for ACRS from analysts
• ACRS’s stock price momentum as measured by its relative strength

About Aclaris Therapeutics Inc (ACRS)

Before we jump into Aclaris Therapeutics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development (R&D;) engine exploring protein kinase regulation. The Company operates through two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment includes provision of laboratory services. The Company is also engaged in identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.

Want to learn more about Aclaris Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc’s Stock Price as of Market Close

As of September 21, 2023, 11:15 AM, CST, Aclaris Therapeutics Inc’s stock price was $6.88.

Aclaris Therapeutics Inc is up 1.62% from its previous closing price of $6.77.

During the last market session, Aclaris Therapeutics Inc’s stock traded between $6.68 and $7.47. Currently, there are 70.63 million shares of Aclaris Therapeutics Inc stock available for purchase.

Unfortunately, Aclaris Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Aclaris Therapeutics Inc Stock Price History

Aclaris Therapeutics Inc’s (ACRS) price is currently down 8.02% so far this month.

During the month of September, Aclaris Therapeutics Inc’s stock price has reached a high of $8.28 and a low of $6.49.

Over the last year, Aclaris Therapeutics Inc has hit prices as high as $18.96 and as low as $5.77. Year to date, Aclaris Therapeutics Inc’s stock is down 52.68%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aclaris Therapeutics Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of September 20, 2023,, no analysts have changed their rating of Aclaris Therapeutics Inc’s stock over the last month.

Additionally, you'll want to evaluate Aclaris Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aclaris Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Aclaris Therapeutics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aclaris Therapeutics Inc (ACRS) by visiting AAII Stock Evaluator.

Relative Price Strength of Aclaris Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 20, 2023, Aclaris Therapeutics Inc has a weighted four-quarter relative price strength of -19.22%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Aclaris Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aclaris Therapeutics Inc Stock Price: Bottom Line

As of September 21, 2023, Aclaris Therapeutics Inc’s stock price is $6.88, which is up 1.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aclaris Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.